Riddhi Siddhi Gluco Biols Ltd is Rated Strong Sell

Understanding the Current Rating

The Strong Sell rating assigned to Riddhi Siddhi Gluco Biols Ltd indicates a cautious stance for investors, signalling significant concerns about the company’s financial health and market prospects. This rating is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment and helps investors understand the risks involved in holding or acquiring this stock.

Quality Assessment

As of 13 April 2026, the company’s quality grade is categorised as below average. This reflects ongoing operational challenges, including persistent losses and weak fundamental strength. The company has reported operating losses, which have adversely affected its ability to generate sustainable earnings. A critical indicator of financial health, the EBIT to Interest ratio, stands at a negative -1.04 on average, signalling difficulties in servicing debt obligations. Additionally, the company’s return on capital employed (ROCE) is negative, underscoring inefficiencies in capital utilisation and a lack of profitability.

Valuation Perspective

Currently, Riddhi Siddhi Gluco Biols Ltd is considered risky from a valuation standpoint. The stock trades at levels that suggest elevated risk relative to its historical averages. Negative EBITDA of ₹-7.68 crores further compounds valuation concerns, as it indicates the company is not generating sufficient earnings before interest, taxes, depreciation, and amortisation. Investors should be wary of the stock’s pricing, which does not appear to offer a margin of safety given the company’s financial difficulties and uncertain outlook.

Financial Trend Analysis

The latest data as of 13 April 2026 reveals a very negative financial trend for Riddhi Siddhi Gluco Biols Ltd. The company has experienced a decline in net sales by 9.59% in the most recent quarter, continuing a pattern of negative results over the last four consecutive quarters. Profit after tax (PAT) for the latest six months stands at ₹13.69 crores, reflecting a sharp contraction of 73.52%. Meanwhile, interest expenses have increased by 47.94% to ₹9.32 crores, placing additional strain on profitability. Net sales for the same period have fallen by 22.58% to ₹72.18 crores, highlighting weakening revenue generation. Over the past year, the stock has delivered a modest return of 0.18%, but profits have plummeted by 75.8%, signalling deteriorating operational performance.

Technical Outlook

From a technical perspective, the stock is rated as mildly bearish. Recent price movements show volatility, with a one-day decline of 3.14%, though the stock has posted gains over one week (+14.44%), one month (+11.05%), and three months (+21.06%). However, the six-month return is negative at -5.24%, and the one-year return is down by 4.81%. These mixed signals suggest short-term momentum may be positive at times, but the overall trend remains cautious. The mildly bearish technical grade aligns with the fundamental challenges faced by the company, reinforcing the recommendation to exercise prudence.

What This Rating Means for Investors

For investors, the Strong Sell rating serves as a clear warning about the risks associated with Riddhi Siddhi Gluco Biols Ltd. The combination of below-average quality, risky valuation, very negative financial trends, and a mildly bearish technical outlook suggests that the stock is currently not a favourable investment. Investors should carefully consider these factors before initiating or maintaining positions, as the company’s financial health and market performance present significant headwinds.

Here’s How the Stock Looks TODAY

As of 13 April 2026, the company remains a microcap player in the Trading & Distributors sector, with a Mojo Score of 6.0, reflecting the strong sell grade. Despite some short-term price rallies, the underlying fundamentals continue to weigh heavily on the stock’s prospects. The persistent operating losses and negative EBITDA highlight ongoing operational inefficiencies. The deteriorating sales and profit figures, coupled with rising interest costs, further exacerbate concerns about the company’s ability to sustain growth or improve profitability in the near term.

Investors should note that while the stock has shown some positive returns over shorter intervals, the overall financial health and valuation metrics do not support a bullish stance. The company’s weak long-term fundamental strength and risky valuation profile suggest that caution is warranted.

Investor Takeaway

In summary, Riddhi Siddhi Gluco Biols Ltd’s current Strong Sell rating reflects a comprehensive assessment of its financial and market position as of 13 April 2026. The company’s below-average quality, risky valuation, very negative financial trends, and mildly bearish technical indicators collectively suggest that the stock carries significant risk. Investors should approach this stock with caution and consider alternative opportunities with stronger fundamentals and more favourable outlooks.

Monitoring the company’s quarterly results and any shifts in operational performance will be crucial for reassessing its investment potential. Until there is clear evidence of improvement in profitability, sales growth, and debt servicing capability, the strong sell recommendation remains appropriate.

Market Context

It is also important to place Riddhi Siddhi Gluco Biols Ltd’s performance in the broader market context. While the stock has experienced some short-term gains, the overall sector and market conditions have been mixed. Investors should weigh the company’s specific challenges against sector trends and macroeconomic factors before making investment decisions.

Conclusion

Riddhi Siddhi Gluco Biols Ltd’s current rating of Strong Sell by MarketsMOJO, last updated on 01 Feb 2025, remains justified by the company’s present-day financial and technical realities as of 13 April 2026. The stock’s risk profile and fundamental weaknesses suggest that it is not suitable for risk-averse investors or those seeking stable returns. Careful analysis and ongoing monitoring are essential for anyone considering exposure to this microcap stock.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →